Regencell Bioscience Holdings Common Stock Net 2020-2024 | RGC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Regencell Bioscience Holdings common stock net from 2020 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Regencell Bioscience Holdings common stock net from 2020 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$247.1B
Amgen (AMGN)	$155.3B
Gilead Sciences (GILD)	$141.6B
Vertex Pharmaceuticals (VRTX)	$99.7B
Bristol Myers Squibb (BMY)	$96B
GSK (GSK)	$80.7B
CSL (CSLLY)	$67.1B
Regeneron Pharmaceuticals (REGN)	$60.7B
Alnylam Pharmaceuticals (ALNY)	$58.2B
Argenex SE (ARGX)	$41.5B
Insmed (INSM)	$27.1B
BioNTech SE (BNTX)	$25.3B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$20B
Incyte (INCY)	$16.6B
Genmab (GNMSF)	$16.2B
Genmab (GMAB)	$15.6B
Illumina (ILMN)	$15.3B
Ascendis Pharma (ASND)	$11.7B
BioMarin Pharmaceutical (BMRN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.9B
Exelixis (EXEL)	$10.2B
Moderna (MRNA)	$9.9B
Verona Pharma American Depositary Share (VRNA)	$9.1B
Bio-Techne Corp (TECH)	$8.9B
Exact Sciences (EXAS)	$8.6B
Halozyme Therapeutics (HALO)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.9B